ACAAI

ACAAI 2025: Peanut patch shows sustained efficacy, safety in toddlers with peanut allergy

November 10, 2025

A long-term study of epicutaneous immunotherapy using the Viaskin Peanut Patch demonstrated continued efficacy and safety in toddlers with peanut allergy, according to research being presented at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting. The therapy delivers microdoses of peanut protein through the skin to gradually desensitize the immune system.

Study details: This open-label extension of the phase 3 EPITOPE trial followed 266 toddlers, including 91 who'd initially received placebo. These children transitioned to active treatment and were monitored for up to 36 months. Tolerance was assessed via double-blind, placebo-controlled food challenges (DBPCFC).

Results: At month 36, 71.2% of former placebo participants tolerated ≥1,000 mg peanut protein (≈3 to 4 kernels), up from 62.7% at month 12. Tolerance to ≥2,000 mg increased from 36.5% to 46.0%. Severe reactions during DBPCFC dropped from 19.2% to 10.0%. No treatment-related anaphylaxis occurred in year 3, and skin reactions decreased over time.

Source:

(2025, November 6). American College of Allergy, Asthma & Immunology. Long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers: Epopex end of study results. [News release]. https://annualmeeting.acaai.org/2025/peanut-patch-treatment.cfm